International Journal of Endocrinology / 2016 / Article / Tab 4

Research Article

Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population

Table 4

Factors influencing radioactive iodine outcome.

SuccessFailure

Age17555.0 (52.8, 57.2)4849.1 (45.3, 52.9)0.0117

GenderF175148 (84.6%)4836 (75.0%)0.122
M27 (15.4%)12 (25.0%)

DiagnosisGD175109 (62.3%)4833 (68.8%)0.369
TMNG60 (34.3%)15 (31.2%)
STA6 (3.4%)0 (0%)

EthnicityNMāori167121 (72.5%)4621 (45.6%)0.001
Māori46 (27.5%)25 (54.4%)

Weight (kg)16174.5 (52.2, 118)4775.2 (53.8, 118.1)0.6674

OphthalmopathyNil10681 (76.4%)3422 (64.7%)
Mild18 (17.0%)8 (23.5%)
Mod.5 (4.7%)2 (5.9%)
Sev.2 (1.9%)2 (5.9%)0.461

T4 at presentation 16427.3 (12.0, 60.1)4639.8 (16.9, 68.0)0.0003

Pretreatment ATD175147 (84.0%)4847 (97.9%)0.011

Length of pretreatment (wks)14644 (13, 335)4757 (13, 556)0.2533

Posttreatment ATD14549 (33.79%)4725 (53.19%)0.018

Length of follow-up (wks)175875 (419, 1466)48961 (456, 1483)0.1148

ATD: antithyroid medication; F: female; M: male; GD: Graves’s disease; TMNG: toxic multinodular goitre; STA: solitary toxic adenoma; NMāori: non-Māori; Mod.: moderate eye disease; Sev.: severe eye disease.
Continuous variables are expressed as mean (95% confidence intervals) or median (5th, 95th percentile) according to their distribution. Categorical variables are expressed as number (percentage).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.